Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Sep 30, 2025 | (FY)Jun 30, 2025 | (Q4)Jun 30, 2025 | (Q3)Mar 31, 2025 | (Q2)Dec 31, 2024 | (Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -124.11%-140.5K | 56.28%-364.98K | -514.08%-152.67K | -88.01%-115.41K | 94.99%-34.2K | 4.17%-62.69K | -529.10%-834.87K | -25.41%-24.86K | -1.50%-61.39K | -4,471.34%-683.2K |
| Net income from continuing operations | -798.93%-977.99K | -30.75%-1.31M | -240.69%-723.71K | -103.69%-393.6K | 84.69%-79.14K | -43.47%-108.8K | 83.98%-998.29K | 96.49%-212.43K | -479.60%-193.23K | -667.87%-516.8K |
| Operating gains losses | ---40.98K | --33.79K | --73.84K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | --114 | -96.50%317 | -76.47%112 | -96.66%111 | -96.35%94 | --0 | 1,180.37%9.07K | 230.05%476 | 618.40%3.32K | 320.59%2.57K |
| Asset impairment expenditure | ---- | --54.31K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Remuneration paid in stock | --546.47K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non cashItems | 657.44%35.09K | -38.27%34.04K | -312.17%-37.84K | 21,796.45%61.75K | -91.10%5.49K | 102.85%4.63K | -99.08%55.14K | -100.15%-9.18K | --282 | --61.75K |
| Change In working capital | 615.68%296.79K | 724.24%817.8K | 144.88%480.61K | 99.90%256.37K | 117.05%39.35K | 664.28%41.47K | -23.94%99.22K | 209.45%196.27K | 527.68%128.25K | -380.27%-230.72K |
| -Change in receivables | -222.14%-4.64K | -39.45%-38.14K | 9.09%-33.35K | --126.74K | -676.11%-130.09K | 89.13%-1.44K | -186.47%-27.35K | -387.15%-36.68K | --0 | 190.24%22.58K |
| -Change in prepaid assets | ---7.6K | ---23.34K | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| -Change in payables and accrued expense | 620.19%309.04K | 594.69%879.28K | 130.65%537.3K | 1.08%129.63K | 166.89%169.44K | 129.72%42.91K | 28.09%126.57K | 359.91%232.95K | 705.31%128.25K | -439.82%-253.3K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -124.11%-140.5K | 56.28%-364.98K | -514.08%-152.67K | -88.01%-115.41K | 94.99%-34.2K | 4.17%-62.69K | -529.57%-834.87K | -26.05%-24.86K | -1.50%-61.39K | -4,471.34%-683.2K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -1.35K | 0 | -1 | 0 | 0 | 0 | ||||
| Net PPE purchase and sale | ---- | ---1.35K | --0 | ---1 | ---- | ---- | --0 | --0 | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---- | ---1.35K | --0 | ---1 | ---- | ---- | --0 | --0 | --0 | ---- |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 112.27%169.77K | -54.23%380.27K | 654.53%154.47K | 187.54%106.41K | -94.65%39.41K | 115.00%79.98K | 1,516.76%830.84K | 29.03%20.47K | 4.18%37.01K | 736.16K |
| Net issuance payments of debt | 78.00%142.36K | 7,047.89%380.27K | 568.37%154.47K | 187.54%106.41K | 142.83%39.41K | 115.00%79.98K | -89.65%5.32K | 45.66%23.11K | 4.18%37.01K | ---92K |
| Net common stock issuance | ---- | --0 | --0 | --0 | ---- | ---- | --956.87K | --43.37K | --0 | ---- |
| Proceeds from stock option exercised by employees | --27.41K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---131.35K | ---46.01K | --0 | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 112.27%169.77K | -54.23%380.27K | 654.53%154.47K | 187.54%106.41K | -94.65%39.41K | 115.00%79.98K | 1,516.76%830.84K | 29.03%20.47K | 4.18%37.01K | --736.16K |
| Net cash flow | ||||||||||
| Beginning cash position | 200.73%20.89K | -39.25%6.95K | 1,394.99%19.09K | 35.06%28.09K | 293.14%24.23K | -39.25%6.95K | -87.13%11.43K | -88.83%1.28K | -42.85%20.8K | -70.31%6.16K |
| Current changes in cash | 69.33%29.27K | 446.19%13.94K | 140.89%1.8K | 63.09%-9K | -92.72%3.86K | 161.26%17.29K | 94.77%-4.03K | -1,406.55%-4.39K | 2.31%-24.38K | 238.87%52.96K |
| Effect of exchange rate changes | --634 | --0 | --0 | --0 | --0 | --0 | -34.90%-460 | 3,049.56%10.06K | --4.86K | ---38.33K |
| End cash Position | 109.60%50.79K | 200.73%20.89K | 200.73%20.89K | 1,394.99%19.09K | 35.06%28.09K | 293.14%24.23K | -39.25%6.95K | -39.25%6.95K | -88.83%1.28K | -42.85%20.8K |
| Free cash from | -124.11%-140.5K | 56.12%-366.33K | -514.08%-152.67K | -88.01%-115.41K | 94.80%-35.55K | 4.17%-62.69K | -529.57%-834.87K | -26.05%-24.86K | -1.50%-61.39K | -4,471.34%-683.2K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.